Table 2. Univariate and multivariate analyses for cancer-specific survival.

	CSS (%)	P value	Univariate analysis	P value	Multivariate analysis	P value
			HR (95% CI)		HR (95% CI)
Age (years)		0.412		0.417	–	–
≤60	33.5		1.000
>60	30.3		1.127 (0.845–1.502)
Gender		0.114		0.120	–	–
Female	45.9		1.000
Male	30.0		1.445 (0.909–2.298)
Tumor length		0.003		0.004	–	–
≤3 cm	42.3		1.000
> 3 cm	28.1		1.642 (1.173–2.297)
Tumor location		0.336		0.342	–	–
Upper/Middle	35.7		1.000
Lower	28.4		1.149 (0.863–1.530)
Vessel invasion		0.003		0.003	–	–
Negative	35.3		1.000
Positive	15.6		1.710 (1.197–2.444)
Differentiation		0.054		0.058	–	–
Well/Moderate	33.8		1.000
Poor	25.5		1.398 (0.989–1.978)
T stage		<0.001		<0.001	–	–
T1-2	45.5		1.000
T3-4	24.7		1.898 (1.382–2.606)
N stage		<0.001		<0.001	–	–
N0	49.3		1.000
N1-3	11.8		2.852 (2.120–3.836)
TNM stage		<0.001		<0.001		<0.001
I	58.0		1.000		1.000
II	38.9		1.966 (1.259–3.067)	0.003	1.825 (1.164–2.861)	0.009
III	13.8		3.799 (2.490–5.736)	<0.001	3.624 (2.362–5.560)	<0.001
Adjuvant therapy		0.085		0.090	–	–
No	35.6		1.000
Yes	24.4		1.297 (0.960–1.753)
CRP (mg/l)		<0.001		<0.001		<0.001
≤ 10.0	39.5		1.000		1.000
> 10.0	13.0		2.066 (1.526–2.798)		1.994 (1.461–2.722)
MPV (fl)		0.019		0.021	–	–
≤ 8.5	41.3		1.000
> 8.5	27.6		1.451 (1.057–1.992)
PC (giga/l)		0.009		0.011	-	-
≤ 200	41.0		1.000
> 200	26.7		1.488 (1.097–2.019)
MPV/PC		<0.001		<0.001		<0.001
> 0.04	43.1		1.000		1.000
≤ 0.04	22.4		1.861 (1.386–2.498)		1.823 (1.347–2.469)
CEA (ng/ml)		0.027		0.031		0.019
≤ 5.0	33.5		1.000		1.000
> 5.0	23.7		1.549 (1.042–2.302)		1.613 (1.082–2.407)
Neu (giga/l)		<0.001		<0.001		0.007
≤ 4.2	43.8		1.000		1.000
> 4.2	19.1		1.945 (1.455–2.600)		1.512 (1.120–2.040)
Neu/PC		0.223		0.229	–	–
≤ 0.02	35.3		1.000
> 0.02	27.1		1.195 (0.894–1.597)

Notes.

ESCC

esophageal squamous cell carcinoma

CRP

c-reactive protein

MPV

mean platelet volume

PC

platelet count

TNM

tumor node metastasis

CEA

carcinoembryonic antigen

Neu

neutrophil

CI

confidence interval

HR

hazard ratio